Publication | Closed Access

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)

Breast OncologyMedicinePharmacologyPhase Iii ProspectiveGynecologyBreast CancerMenopausePharmacotherapySakk 20/90Second-line Hormonal TreatmentOncologyEndocrine-related CancerMenopause Hormone Therapy